AstraZeneca completes acquisition of Takeda’s respiratory business

AstraZeneca has completed its acquisition of pharmaceutical company Takeda’s respiratory business.

The deal, which was first announced in December last year, was completed today, May 5, AstraZeneca said in a statement.

The agreement covers the rights to the Daliresp (roflumilast) drug which is used in the treatment of chronic obstructive pulmonary disease.

Under the terms of the agreement, AstraZeneca will make a payment of $575 million to Takeda.